Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company?s proprietary bead technology used to perform diagnostic and research assays on samples. This segment?s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.